Cobolimab is a monoclonal antibody commercialized by GSK, with a leading Phase III program in Squamous Non-Small Cell Lung Cancer. According to Globaldata, it is involved in 7 clinical trials, of which 1 was completed, and 6 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Cobolimab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Cobolimab is expected to reach an annual total of $34 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Cobolimab Overview

Cobolimab is under development for the treatment of solid tumors including melanoma, non-small cell lung cancer, metastatic hepatocellular carcinoma and colorectal cancer. It inhibits T cell immunoglobulin mucin-3 (TIM-3). The drug candidate is a humanized monoclonal IgG4 antibody and is administered through intravenous route. It is based on the (somatic hypermutation) SHM-XEL technology.

GSK Overview

GSK is a healthcare company that focuses on developing, manufacturing and commercializing pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.

The company reported revenues of (British Pounds) GBP29,324 million for the fiscal year ended December 2022 (FY2022), an increase of 18.7% over FY2021. The operating profit of the company was GBP6,433 million in FY2022, compared to an operating profit of GBP4,321 million in FY2021. The net profit of the company was GBP14,751 million in FY2022, compared to a net profit of GBP3,874 million in FY2021.

For a complete picture of Cobolimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.